{"id":575321,"date":"2025-10-09T00:00:00","date_gmt":"2025-10-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0061-biopharma-graft-versus-host-disease-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:24:47","modified_gmt":"2026-03-31T10:24:47","slug":"epidim0061-biopharma-graft-versus-host-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0061-biopharma-graft-versus-host-disease-epidemiology-mature-markets\/","title":{"rendered":"Graft Versus Host Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of graft versus host disease (<abbr title=\"graft versus host disease\">GVHD<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed events and the diagnosed prevalence of <abbr title=\"graft versus host disease\">GVHD<\/abbr> for each country, as well as annualized counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"graft versus host disease\">GVHD<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and increasing life expectancy, affect the epidemiology of <abbr title=\"graft versus host disease\">GVHD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 10 <abbr title=\"graft versus host disease\">GVHD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed allogeneic <abbr title=\"hematopoietic stem-cell transplantation\">HSCT<\/abbr> events.<\/li>\n<li>Diagnosed acute <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed chronic <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed grade l acute <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed grade ll acute <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed grade lll acute <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed grade lV acute <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed limited chronic <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed extensive chronic <abbr title=\"graft versus host disease\">GVHD<\/abbr> events.<\/li>\n<li>Diagnosed chronic <abbr title=\"graft versus host disease\">GVHD<\/abbr> prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-575321","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-graft-versus-host-disease","biopharma-therapy-areas-transplant","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575321\/revisions"}],"predecessor-version":[{"id":575727,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575321\/revisions\/575727"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}